A UK-led clinical trial has opened at The Christie NHS Foundation Trust in Manchester to test a new drug that could make immunotherapy safer and more accessible for patients with multiple myeloma. 

The trial, called TOPICAL, is led by The Christie NHS Foundation Trust and will take place at five other NHS hospitals in the UK. 

TOPICAL will study whether an experimental anti-inflammatory treatment, known as POLB 001, can help prevent a common side effect called cytokine release syndrome (CRS), a potentially dangerous immune reaction that can occur following cancer immunotherapy treatments. 

CRS causes severe flu-like symptoms including high fever, dangerously low blood pressure, breathing difficulties and, in some cases, the condition can be life-threatening. Nearly a quarter of patients who develop severe CRS require intensive care. Studies show that over 70% of patients receiving some cancer immunotherapies are affected by CRS. 

Dr Emma Searle, Consultant Haematologist at The Christie, who is the chief investigator on the TOPICAL trial said: “Immunotherapy treatments are transforming survival rates for patients with difficult-to-treat blood cancers, but their use will continue to be restricted until we find a way to deliver them safely outside of specialist hospitals. Ultimately, our aim is to help more patients benefit from these life-saving therapies while reducing the burden of treatment on patients, families and the NHS.” 

The TOPICAL trial plans to recruit around 30 patients with relapsed or treatment-resistant multiple myeloma. Participants will receive POLB 001 alongside bispecific antibody teclistamab. 

POLB 001 is being developed by Poolbeg Pharma and works by targeting inflammatory pathways involved in CRS. 

The TOPICAL trial is contributing to the RISE programme, a Manchester-led research project funded via the Medical Research Council Prosperity Partnership award, which is one of the biggest studies ever undertaken into the side effects of blood cancers.